Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study

被引：2
|
作者：
Shi, Minke [1 ]
Ma, Jing [2 ]
Feng, Meilin [2 ]
Liang, Lei [3 ]
Chen, Hongyuan [3 ]
Wang, Tao [1 ]
Xie, Zhenghua [3 ]
机构：
[1] Nanjing Univ, Nanjing Drum Tower Hosp, Dept Thorac Surg, Affiliated Hosp,Med Sch, Nanjing, Peoples R China
[2] 3D Med Inc, Dept Data Syst, Shanghai, Peoples R China
[3] 3D Med Inc, Dept Res & Dev, Shanghai, Peoples R China
来源：
CANCER GENETICS | 2021年 / 256卷
关键词：
MET alterations; MET exon 14 skipping analog; NGS; Oncogenic driver; MET; MUTATIONS; NONSENSE; INHIBITORS; MECHANISM; MISSENSE;
D O I：
10.1016/j.cancergen.2021.04.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MET exon 14 skipping (METex14) is a validated oncogenic driver in lung cancer and MET tyrosine kinase inhibitors are now available as effective clinical treatments. The majority of known METex14 alterations are typical donor/acceptor splicing or ubiquitination site mutations. Herein, two new METex14 variants were detected in two patients with lung adenocarcinoma by targeted next generation sequencing (NGS). Reverse transcription (RT)-based analysis confirmed that these mutations led to MET exon 14 skipping. Our analysis provided evidence for possible targeted therapy options for patients carrying these MET mutations or similar METex14 analogs. (c) 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码：62 / 67
页数：6
相关论文
共 50 条
  • [21] Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
    Digumarthy, Subba R.
    Mendoza, Dexter P.
    Zhang, Eric W.
    Lennerz, Jochen K.
    Heist, Rebecca S.
    CANCERS, 2019, 11 (12)
  • [22] MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American Non-Small-Cell Lung Cancer Patients
    Rivas, Solange
    Sepulveda, Romina V.
    Tapia, Ignacio
    Estay, Catalina
    Soto, Vicente
    Blanco, Alejandro
    Gonzalez, Evelin
    Armisen, Ricardo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (24)
  • [23] Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case Report
    Kleemiss, Moritz
    Mueller, Christa E.
    Schneider, Marion
    Strotmann, Rainer
    Orlowski, Katrin
    Goteti, Kosalaram
    Yanik, Mert
    Brossart, Peter
    Bauernfeind, Franz-Georg
    CLINICAL LUNG CANCER, 2024, 25 (06) : 577 - 580
  • [24] MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experience
    R. Ben Dhiab
    R. Loyaux
    S. Garinet
    M. Bastide
    S. Léonard-Goyet
    Elizabeth Fabre
    Audrey Mansuet-Lupo
    Laure Gibault
    S. Jouveshomme
    E. Giroux-Leprieur
    K. Leroy
    M. Wislez
    H. Blons
    Scientific Reports, 15 (1)
  • [25] Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States
    Cai, Beilei
    Zhou, Zheng-Yi
    Xue, Weiguang
    Hazra, Nisha C.
    Singh, Mukesh
    Mishra, Dinesh
    Brixner, Diana
    Oderda, Gary
    Biskupiak, Joseph
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 131 - 139
  • [26] Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study
    Babey, Helene
    Jamme, Philippe
    Curcio, Hubert
    Assie, Jean Baptiste
    Veillon, Remi
    Doubre, Helene
    Perol, Maurice
    Guisier, Florian
    Huchot, Eric
    Decroisette, Chantal
    Falchero, Lionel
    Corre, Romain
    Cortot, Alexis
    Chouaid, Christos
    Descourt, Renaud
    TARGETED ONCOLOGY, 2023, 18 (04) : 585 - 591
  • [27] Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and MET Exon 14 Skipping Mutations: A Descriptive Analysis From the US
    Kolaei, Fatemeh Asad Zadeh Vosta
    Cai, Beilei
    Kanakamedala, Hemanth
    Kim, Julia
    Doban, Vitalii
    Zhang, Shiyu
    Shi, Michael
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] MET Exon 14 Variants in Non-Small Cell Lung Carcinoma: Prevalence, Clinicopathologic and Molecular Features
    Yuan, Lisi
    Mehrotra, Harshita
    He, Xin
    Bosler, David
    JOURNAL OF MOLECULAR PATHOLOGY, 2023, 4 (01): : 46 - 56
  • [29] Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
    Drilon, A.
    Clark, J.
    Weiss, J.
    Ou, S.
    Camidge, D. R.
    Solomon, B.
    Otterson, G.
    Villaruz, L.
    Riely, G.
    Heist, R.
    Shapiro, G.
    Murphy, D.
    Wang, S.
    Usari, T.
    Li, S.
    Wilner, K.
    Paik, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S348 - S348
  • [30] MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life
    Drilon, Alexander
    CLINICAL CANCER RESEARCH, 2016, 22 (12) : 2832 - 2834
12345